glioblastoma

New York Genome Center, Rockefeller University, and IBM researchers combined whole-genome sequencing with Watson to analyze a glioblastoma sample.

Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.

For the first time, the researchers also found a clear difference in risk factors for high-grade glioblastoma versus low-grade glioma.

Mutation and expression patterns in longitudinal, multifocal, and solitary tumor samples suggest glioblastoma follows a multiverse model of evolution.

Tempus will provide sequencing and analysis for glioblastoma patients in a clinical trial at Duke using engineered poliovirus as a treatment.

Investigators explored computational strategies for identifying microRNAs that are most relevant to tumor development and progression.

The research team established that its model can be used to determine the optimal dose of radiation therapy for individual patients. 

Dartmouth researchers characterized 5-methylcytosine and 5-hydroxymethylcytosine marks in more than two dozen glioblastoma samples.

Short tandem repeat and expression data indicate that the U87MG cell line in the ATCC collection no longer represents the glioma from which it was established.